{
    "eid": "2-s2.0-85008251787",
    "title": "Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A",
    "cover-date": "2017-04-01",
    "subject-areas": [
        {
            "$": "Pharmacology",
            "@code": "3004"
        },
        {
            "$": "Pharmacology (medical)",
            "@code": "2736"
        }
    ],
    "keywords": [],
    "authors": [
        "T. Prueksaritanont"
    ],
    "citedby-count": 110,
    "ref-count": 47,
    "ref-list": [
        "Membrane transporters in drug development",
        "Drug-drug interaction studies: Regulatory guidance and an industry perspective",
        "In vitro methods to support transporter evaluation in drug discovery and development",
        "Validation of the five-drug 'Pittsburgh cocktail' approach for assessment of selective regulation of drug-metabolizing enzymes",
        "Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the 'Cooperstown cocktail'",
        "The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting - Proposal of a Four Component Transporter Cocktail",
        "Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin",
        "European Medicines Agency (EMA) Committee for Human Medicinal Products (CHMP): guideline on the investigation of drug interactions: final",
        "Transporter-mediated drug-drug interactions involving OATP substrates: Predictions based on in vitro inhibition studies",
        "Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin",
        "Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers",
        "Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo",
        "Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin",
        "Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver",
        "Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans",
        "Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I",
        "The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects",
        "Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans",
        "Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of fibrates and rifampicin",
        "Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data",
        "Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies",
        "Pitavastatin concentrations are not increased by CYP3A4 inhibitor itraconazole in healthy subjects",
        "A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: Application with clarithromycin",
        "Effect of itraconazole on the pharmacokinetics of rosuvastatin",
        "Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism",
        "Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study",
        "Effect of itraconazole on the pharmacokinetics of atorvastatin",
        "Comparative pharmacokinetic interaction profiles of Pravastatin, Simvastatin, and Atorvastatin when coadministered with cytochrome P450 inhibitors",
        "Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin",
        "Evaluation of ketoconazole and its alternative clinical CYP3A4/5 inhibitors as inhibitors of drug transporters: The in vitro effects of ketoconazole, ritonavir, clarithromycin, and itraconazole on 13 clinically-relevant drug transporters",
        "Role of P-glycoprotein inhibition for drug interactions: Evidence from in vitro and pharmacoepidemiological studies",
        "Drug and Bile Acid Transporters in Rosuvastatin Hepatic Uptake: Function, Expression, and Pharmacogenetics",
        "Predicting carrier-mediated hepatic disposition of rosuvastatin in man by scaling from individual transfected cell-lines in vitro using absolute transporter protein quantification and PBPK modeling",
        "Hepatic uptake of atorvastatin: Influence of variability in transporter expression on uptake clearance and drug-drug interactions",
        "Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: Implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs",
        "Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments",
        "Guidance for industry, drug interaction studies\u2014study design, data analysis, implications for dosing, and labeling recommendations",
        null,
        "Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: A clinical microdosing study",
        "The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans",
        "Drug-drug interaction between pitavastatin and various drugs via OATP1B1",
        "ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin",
        "Transporter pharmacogenetics and statin toxicity",
        "Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin",
        "Validation of 4\u03b2-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects",
        "The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia",
        "Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers"
    ],
    "affiliation": [
        {
            "affiliation-city": "Rahway",
            "affilname": "Merck &amp; Co., Inc.",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Lincoln",
            "affilname": "Celerion, USA",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "San Diego",
            "affilname": "Abide Therapeutics",
            "affiliation-country": "United States"
        }
    ],
    "funding": []
}